Navigation Links
New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone)
Date:6/10/2008

adiversion.usdoj.gov/drugs_concern/oxycodone/oxycodone.htm" target="_new">http://www.deadiversion.usdoj.gov/drugs_concern/oxycodone/oxycodone.htm

About Chronic Pain

Approximately 50 million Americans suffer with chronic pain, a distinct type of pain, often with no cure. It can affect an individual throughout his or her life, lasting several weeks, months, or even years at a time. The onset of chronic pain may be nociceptive (caused by ongoing tissue injury), neuropathic (caused by damage to the brain, spinal cord, or peripheral nerves), or disease specific (such as osteoarthritis or cancer).

Corporate Relationships

In December 2002, DURECT licensed to Pain Therapeutics, Inc. the right to develop and commercialize on a worldwide basis Remoxy and other oral sustained release drug candidates using the ORADUR technology which incorporate four specified opioid compounds. Under the license agreement, DURECT is reimbursed for formulation and other work performed under its agreement with Pain Therapeutics, and will receive additional payments if certain development and regulatory milestones are achieved with respect to the licensed drug candidates. In addition, if commercialized, DURECT will receive royalties for Remoxy and certain other licensed drug candidates of between 6.0% to 11.5% of net sales of the drug candidate depending on sales volume as well as a mark-up on DURECT's supply of key excipients used in the manufacture of the licensed drug candidates. Pain Therapeutics sublicensed the commercialization rights to Remoxy and other licensed drug candidates to King Pharmaceuticals in November 2005.

About ORADUR

ORADUR is a proprietary technology designed to transform short-acting oral capsule dosage forms into sustained release oral products, with the added benefit of being less prone to abuse than other controlled release dosage forms on the market today.

About DURECT Corporation

DURECT is an emerging specialt
'/>"/>

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... ANDS ) announced today that it will present ... on Tuesday,March 4, 2008 at 4:30 p.m. EST (1:30 ... Hotel in New York., Steve Worland, Ph.D., President ... an overview of Anadys and its two,development-stage product candidates, ...
... Vermillion, Inc.,(Nasdaq: VRML ) announced that on February ... Market LLC that indicated the Company is not in,compliance ... (i),a minimum of $2,500,000 in stockholders, equity; (ii) $35,000,000 ... net income from continuing,operations for the most recently completed ...
... Ltd., a wholly owned subsidiary of Forest Laboratories, ... and Mylan Inc. (NYSE: MYL ) have,amended ... the novel beta blocker Bystolic(TM) (nebivolol), which is,currently ... of hypertension.,The companies have agreed that Forest will ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference 2Vermillion Receives NASDAQ Notice of Non-Compliance 2Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement 2Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement 3
(Date:4/17/2014)... State University engineer has developed a patented technique ... explosive devices. The same technique could help police ... M. and Kay L. Theede chair in engineering ... and his research team have created a template-based ... car trunks. The distance detection method called ...
(Date:4/17/2014)... release is available in German . ... pay the protection money demanded of him, he can expect ... required, however, as fear of the consequences is enough to ... in parasitic birds, which lay their eggs in other birds, ... the brood parasites take their revenge by destroying the entire ...
(Date:4/17/2014)... conditions such as heart disease, epilepsy and pain, making ... there is still much scientists do not know about ... insight into the structure of sodium channels and, specifically, ... are responsible for ,fine-tuning, the activity of the channel. ... of the Journal of Biological Chemistry . , ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Structure of sodium channels different than previously believed 2
... a devastating wheat fungus isn,t threatening the state,s crops yet. ... the U.S. Department of Agriculture to keep it that way. ... leading a group of researchers to study the wheat blast ... Brazil. "We don,t know if our varieties in Kansas ...
... In the rogues, gallery of microscopic infectious agents, the prion ... both DNA and RNA, prions are believed to cause such ... and moose, mad cow disease in cattle, scrapie in sheep ... the weirdest infectious agent know to science, the prion is ...
... repair patterns may increase risk of pancreatic cancer by as ... 77 percent, depending on the genes involved, according to a ... Clinical Cancer Research , a journal of the American Association ... in late stages, and thus is resistant to most available ...
Cached Biology News:Researchers to use K-State's BSL-3 Lab for $1 million study of fungus threatening wheat crops 2Researchers to use K-State's BSL-3 Lab for $1 million study of fungus threatening wheat crops 3Common soil mineral degrades the nearly indestructible prion 2
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Biology Products: